Atea Pharmaceuticals, Inc. · NASDAQ:AVIR
Atea Pharmaceuticals — Q3 2024 Earnings Presentation
18 slides from Atea Pharmaceuticals's earnings presentation, Nov 7, 2024
Slide 1: Third Quarter Financial and Business Update
Third Quarter Financial and Business Update November 7, 2024 NASDAQ: AVIR June 2020
Slide 2: Disclaimers: Forward-Looking Statements
DISCLAIMERS Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our curr
Slide 3: Antiviral Pipeline Targeting Large Market Opportunities
Antiviral Pipeline Targeting Large Market Opportunities THERAPEUTIC PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MAJOR MILESTONES INDICATION Bemnifosbuvir Hepatitis C Bemnifosbuvir + Ruzasvir Nucleotide • Phase 2 SVR12 results Q4’24 Combination (N=275) Program Ruzasvir* • End of Phase 2 meeting with
Slide 4: Bemnifosbuvir + Ruzasvir Global Phase 3-Ready Program
HEPATITIS C Bemnifosbuvir + Ruzasvir Global Phase 3-Ready Program Derisked Program, Potential “Best in Class” Profile with Long Patent Life Manufacturing Regulatory Clinical Operations Intellectual Property • Fixed dose • Planning for End of • Global clinical trial • Broad global combination tablet
Slide 5: Today's HCV Patient Profile / US Antiviral Market Opportunity for HCV
HEPATITIS C HCV Today’s HCV Patient Profile US Antiviral Market Opportunity for HCV
Slide 6: Profile of Today's HCV-Infected Patient
HEPATITI S C Profile of Today’s HCV-Infected Patient Predominately Younger Patient Population (20-49 yrs old)1, Newly Infected1 Therefore <10% Cirrhotic2 Unmet Need for Convenient Therapy Unmet Need Due to DDIs Populations at highest risk for High proportion of current HCV- HCV infection are frequen
Slide 7: Today's HCV Patients Present New Challenges and Need Improved Drug Profile
HEPATITI S C Today’s HCV Patients Present New Challenges and Need Improved Drug Profile 94% of Epclusa® and Mavyret® Prescribers Stated Continuing Unmet Medical Needs in Rigorous Quantitative Market Research Study1 Treatment Adherence Concomitant Medications Taking with Food is a Challenge • Patient
Slide 8: US HCV Market: Epclusa & Mavyret
HEPATITIS C US HCV Market: Epclusa® & Mavyret® Potential US HCV 2022 2023 1H 2024 Market Value Treatment of all # of Patients (NRxs) Treated 1 93,452 98,412 46,901 current chronic HCV patients >$20B+ Potential Market Value3 2023 Total US HCV Market $1,599M $1,518M $826M ~2-4M 4 Net Revenues 2 ~$1.5B
Slide 9: Program Review: Potential Best-in-Class Pan-Genotypic Regimen
HEPATITIS C Program Review: Potential Best-in-Class Pan-Genotypic Regimen • Phase 2 Open Label Study of Bemnifosbuvir + Ruzasvir
Slide 10: Phase 2 Open Label Study of BEM + RZR in HCV Patients
HEPATITIS C Phase 2 Open Label Study of BEM + RZR in HCV Patients BEM 550 mg QD Study Design: Open label combination Results in Q4 2024 N= 275 patients: including lead-in cohort RZR 180 mg QD 8 weeks dosing w/combination Patient Population: Primary Endpoints: • HCV-infected patients, including • SVR
Slide 11: Efficacy Analysis Populations
HEPATITI S C Efficacy Analysis Populations Phase 2 Open Label Study of BEM + RZR Total Enrolled (N=275) Per-Protocol Per-Protocol Population Treatment Adherent Regardless of Adherence* Population is Primary Efficacy Population for Phase 2 Study Per-Protocol Treatment Adherent Population Primary Endp
Slide 12: HCV RNA Results – All Genotypes (N=60)
HEPATITI S C HCV RNA Results – All Genotypes (N=60) Phase 2 Open Label Study of BEM + RZR Lead-in Cohort1 • 97% SVR12 in lead-in cohort in per-protocol population regardless of treatment adherence (efficacy evaluable) • 2 subjects (GT1b and GT2b) with post-treatment relapse • Low plasma drug levels
Slide 13: On-treatment Viral Kinetics – Individual Patient Data (n=60)
HEPATITI S C On-treatment Viral Kinetics – Individual Patient Data (n=60) Phase 2 Open Label Study of BEM + RZR Lead-in Cohort • Rapid viral reduction in all patients within the first week HCV RNA, log10 IU/mL regardless of baseline viremia and genotype • Viral load in all patients near or below LLO
Slide 14: Open Label Phase 2 Lead-in Cohort Results (n=60)
HEPATITI S C Open Label Phase 2 Lead-in Cohort Results (n=60) Phase 2 Open Label Study of BEM + RZR Lead-in Cohort Safety Summary • All patients (n=60) completed the 8-week treatment period • Bemnifosbuvir + ruzasvir was generally safe and well tolerated • No drug-related SAEs or premature treatment
Slide 15: Financial Summary
Financial Summary 15
Slide 16: Financial Update Third Quarter 2024
Financial Update Third Quarter 2024 16
Slide 17: Financial Update Third Quarter 2024
Financial Update Third Quarter 2024 17
Slide 18: Closing Remarks
Closing Remarks Corporate Presentation NASDAQ: AVIR June 2020